Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprian Therapeutics, Inc., on Tuesday said the U.S. Food and Drug Administration has approved ZYCUBO for the treatment of Menkes disease in pediatric patients. Until now, there has been no approved treatment for the rare disorder in the United States.
Menkes disease is a rare X-linked recessive pediatric disorder caused by mutations in the copper transporter ATP7A gene.
In December 2023, Sentynl Therapeutics, a unit of Zydus Lifesciences, secured the rights to develop and commercialize ZYCUBO from Cyprium. Under the agreement with Sentynl, a Rare Pediatric Disease Priority Review Voucher (PRV) issued with FDA approval will be transferred to Cyprium. The company is also eligible for tiered royalties on ZYCUBO sales and up to $129 million in development and sales milestones from Sentynl.
The approval is supported by positive topline clinical results, which showed that early treatment with ZYCUBO significantly improved overall survival in Menkes disease patients compared with an untreated contemporaneous external control cohort, reducing the risk of death by nearly 80%.
Fortress Biotech shares rose more than 5% in pre-market trading, after closing at $4.20 on Monday, down 2.32%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.